Overview of the Gastric Cancer Treatment Market

According to DataM Intelligence, the global Gastric Cancer Treatment Market size was approximately US$5.82 billion in 2024 and is forecasted to reach US$14.66 billion by 2033, growing at a CAGR of around 11.5% during 2025-2033.

The gastric cancer treatment market is witnessing significant growth globally, driven by the rising incidence of gastric cancer, expanding research on targeted and immunotherapies, and improved healthcare infrastructure. Treatment modalities for gastric cancer vary depending on stages and specific tumor characteristics such as HER2 expression and PD-L1 status. They include surgery, chemotherapy, radiation therapy, targeted therapies, and immunotherapy. The introduction of advanced therapies such as checkpoint inhibitors (e.g., pembrolizumab) and antibody-drug conjugates (e.g., trastuzumab deruxtecan) is shaping personalized treatment approaches leading to improved survival rates and quality of life.

𝗚𝗲𝘁 𝗮 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 (𝗨𝘀𝗲 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝗘𝗺𝗮𝗶𝗹 𝗜𝗗 𝗳𝗼𝗿 𝗮 𝗤𝘂𝗶𝗰𝗸 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲): https://www.datamintelligence.com/download-sample/gastric-cancer-treatment-market?jd

Market Segmentation

By Cancer Type (Non-Cardia (Distal) Stomach Cancer, Proximal Stomach Cancer, Diffuse Stomach Cancer, Lymphomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, Adenocarcinoma, Others)
By Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Surgery, Others)
By Route of Administration (Injectable, Oral)

Regional Market Insights

Asia-Pacific holds the largest market share due to the high incidence of gastric cancer cases, government initiatives to improve cancer care and early diagnosis, and growing healthcare expenditure. China and Japan especially invest significantly in gastric cancer research and new treatment introductions. North America and Europe exhibit robust growth driven by innovative R&D activities, clinical trials, and favorable reimbursement policies supporting advanced therapeutics. Increasing adoption of personalized medicine and molecular diagnostic tests in these regions further propels market expansion.

Market Drivers

• Increasing Gastric Cancer Incidence: Rising prevalence worldwide, especially related to lifestyle factors such as Helicobacter pylori infection, smoking, and obesity.
• Advancements in Targeted and Immunotherapies: Development of novel agents that provide better efficacy with fewer side effects drives adoption.
• Improved Early Diagnosis: Widespread use of endoscopy and biopsy technologies lead to timely and tailored treatments.
• Government and Private Sector Support: Investments in healthcare infrastructure and oncology research boost market growth.
• Growing Awareness and Screening Programs: Lead to higher detection rates and demand for effective treatment options.
• Personalized Medicine: Expansion of genetic and biomarker testing facilitates targeted treatment approaches, improving patient outcomes.

Recent Developments

In March 2025, the FDA approved pembrolizumab (Keytruda) in combination with trastuzumab and chemotherapy for first-line treatment of HER2-positive gastric or gastroesophageal junction cancer following the KEYNOTE-811 trial outcomes.

Several companies are conducting advanced clinical trials of next-generation targeted agents such as bemarituzumab and zanidatamab, aiming to improve survival in advanced gastric cancer.

Key Players

Leading pharmaceutical companies dominate the gastric cancer treatment market through innovative drug development and extensive clinical pipelines:

• Roche Holding AG: Leader in HER2-targeted therapies like trastuzumab.
• Merck & Co., Inc.: Pioneer in immunotherapy with Keytruda (pembrolizumab).
• Bristol-Myers Squibb: Active in immune checkpoint inhibitors.
• AstraZeneca: Developing new targeted therapies and antibody-drug conjugates.
• Eli Lilly and Company: Significant pipeline in oncology.
• Daiichi Sankyo: Collaborated with AstraZeneca for trastuzumab deruxtecan.
• Ono Pharmaceutical Co. Ltd.: Key immuno-oncology player.
• Sanofi S.A.: Expanding its gastric cancer portfolio.

Conclusion

The gastric cancer treatment market is on a progressive growth path backed by rising patient incidence, substantial therapeutic innovation, and increasing healthcare investments globally. With the dominance of gastric adenocarcinoma, the market is witnessing a shift toward precision oncology, immunotherapy, and combination treatment regimens that promise improved survival and quality of life. Asia-Pacific leads due to high disease burden and expanding healthcare infrastructure, while North America and Europe exhibit strong innovation and adoption of novel drugs. Key market players like Roche, Merck, and AstraZeneca are shaping the landscape through strategic collaborations and pipeline advancements. As screening, diagnosis, and personalized treatment evolve, the gastric cancer treatment market is expected to sustain strong growth through 2033, providing vital opportunities for stakeholders focused on delivering comprehensive patient care and novel therapeutic modalities.

About DataM Intelligence

DataM Intelligence is a Market Research and Consulting firm providing end-to-end business solutions from Research to Consulting. Their research database features over 6300 reports across 40+ domains, serving more than 200 companies in 50+ countries.

Contact Us:

Company: DataM Intelligence 4Market Research LLP

Contact: Sai Kiran

Email: Sai.k@datamintelligence.com 

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com